Acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection is uncommon in children [1], with greater
morbidity and mortality in adults and elderly. A number of hypotheses may
explain the low susceptibility of children to COVID-19 virus
[2] viz, (i) immaturity and limited function
of angiotensin-converting enzyme 2 (ACE2) receptors in
children, as undifferentiated cells that express low levels
of ACE2 are not readily infected by SARS-CoV; (ii)
the immature innate immune system in young children results
in less inflammation and consequently fewer symptoms; and, (iii)
possible cross-reactivity of antibodies against other
viruses (influenza, adenovirus, respiratory syncytial virus
etc.) with the SARS-CoV-2, which could provide
partial protection.
As COVID-19 infection is not universally mild in children
[3], it is important that they are protected as a vulnerable
population, as still there is limited data on the risk
factors for severe infection in children.
The long-term effects on the lungs of COVID-19 in children
are not known, even for those with moderate symptoms. In
patients hospitalized in French pediatric units in recent
weeks, the chest computed tomography (CT) scans have often
been pathological, even in children with limited respiratory
sign with associated decline in lung function (unpublished
data). In light of this, should not all children with
moderate to severe respiratory symptoms be treated,
irrespective of their comorbidity? Why do pediatricians
appear to be unwilling to consider employing the COVID-19
treatments that are available, e.g., hydroxychloroquine and
azithromycin [4]?
These drugs (which are already widely used in
pediatrics in other indications) certainly have side effects
that are of concern, but their use in a hospital environment
shall allow these side effects to be monitored and ensure
greater safety for the patient [5].
In the absence of specific antiviral treatments,
pediatricians need more virological, epidemiological, and
clinical data to better treat and manage COVID-19
infections. It should be kept in mind that children, even
when asymptomatic, may be a potential cause of spread and
transmission of the disease in their communities [6]. In light of this, barrier precaution needs to be
rigorously applied within families in order to protect the
elderly.
Funding:
None; Competing interest: None stated.
REFERENCES
1 Dong Y, Mo X, Hu Y,
Qi X, Jiang F, Jiang Z, et al. Epidemiological
characteristics of 2143 pediatric patients with 2019
coronavirus disease in China. Pediatrics. 2020. Available
from:
https://pediatrics.aappublications.org/content/pediatrics/early/2020/03/16/peds.2020-0702.full.
pdf. Accessed April 24, 2020.
2. Li Y, Guo F, Cao Y, Li L, Guo Y. Insight into COVID 2019
for pediatricians. Pediatric Pulmonol. 2020;55:E1-E4.
3. Sun D, Li H, Lu X, Xiao H, Ren J, Zhang FR, et al.
Clinical features of severe pediatric patients with
coronavirus disease 2019 in Wuhan: A single center’s
observational study. World J Pediatr. 2020 Mar 19: 1-9.
Available from: https://
www.ncbi.nlm.nih.gov/pmc/articles/PMC7091225. Accessed
April 26, 2020.
4. Colson P, Rolain JM,
Raoult D. Chloroquine for the 2019 novel coronavirus
SARS-CoV-2. Int J Antimicrob Agents. 2020;55:105923.
5. Ponticelli C, Moroni
G. Hydroxychloroquine in systemic lupus erythematosus (SLE).
Expert Opin Drug Saf. 2017;16:411-9.
6. Bai Y, Yao L, Wei T,
Tian F, Jin DY, Chen L, et al. Presumed asymptomatic
carrier transmission of COVID-19. JAMA. 2020;323:1406-7.